Completed PHASE2 INTERVENTIONAL NCT00211484

Treatment of Conditions With Open Label-Anecortave Acetate Sterile Suspension ( 15mg.) Where Lesions do Not Meet Acceptable Criteria for Standard Care.

Sponsor: Alcon Research

Conditions Age-Related Macular Degenerations. Subfoveal Neovascularization.

Updated 5 times since 2017 Last updated: May 4, 2007 Started: May 31, 2003 Completion: Mar 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00211484, this PHASE2 trial focuses on Age-Related Macular Degenerations. and Subfoveal Neovascularization. and remains completed. Sponsored by Alcon Research, it has been updated 5 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alcon Research
Manhattan Eye, Ear & Throat Hospital

Data source: Manhattan Eye, Ear & Throat Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States